In order to break the competition in the same industry, this Chinese medicine tablet company has a new action!

【Pharmaceutical Network Industry News】Chinese medicine tablets are one of the three pillars of China's traditional Chinese medicine industry, which is in the middle link of the traditional Chinese medicine industry and plays a role
in the traditional Chinese medicine industry.
In recent years, with the support of favorable policies, as well as the intensification of population aging and the continuous upgrading of consumption, the Chinese medicine tablet industry has continued to develop, and in addition, in the context of the increase in demand for Chinese medicine formula granules, the application of the upstream Chinese medicine tablet industry has also increased
.
In the first half of 2022, Chinese medicine tablets achieved revenue of 100.
5 billion yuan, an increase of 6.
9% year-on-year; The total profit of Chinese medicine tablets was 7.
88 billion yuan, which continued to increase by 20.
3%
year-on-year.
The scale of the Chinese medicine tablets market is huge, but the current industry concentration is still relatively low, and many pharmaceutical companies have competition in the same industry in the Chinese medicine tablet business
.
In order to enhance its competitiveness, ConnBei recently announced that the company intends to transfer 51% of the equity of Zhejiang University of Chinese Medicine Tablets Co.
, Ltd.
(hereinafter referred to as "University of Chinese Medicine Tablet Company") held by the controlling shareholder, Provincial Health Industry Group, for 170 million yuan (RMB, the same below), and agree to the 51% equity transfer agreement
signed between the company and the Provincial Health Industry Group on the Chinese Medicine University Drinking Tablet Company 。 It is reported that the University of Chinese Medicine Tablet Company is mainly engaged in the production and sales of traditional Chinese medicine tablets, for the combination of production, education and research in Zhejiang Province, the production and processing enterprises of traditional Chinese medicine tablets, with the layout of two major production bases in Hangzhou Fuyang and Quzhou Changshan, with a production capacity of about 6,000 tons / year and a production capacity of about 7,000 pieces / day, and has gradually formed a complete industrial chain
of traditional Chinese medicine integrating medicinal material planting, product research and development, traditional Chinese medicine production and sales, medical investment, etc 。 For this transaction, Kang Enbei said that the University of Chinese Medicine Tablet Company has a more prominent advantage in the integration of production, education and research, which is conducive to promoting the integration and coordinated development of the company's resources related to Chinese medicine tablets, giving full play to the company's relatively solid industrial foundation in the planting of Chinese herbal medicines, processing of Chinese medicine tablets, and manufacturing of proprietary Chinese medicines, and enhancing the company's competitiveness
in the business of Chinese medicine tablets.
It is worth mentioning that Conn Bay has made frequent moves this year, adding and subtracting
.
On August 12, Kang Enbei announced that it intends to transfer
the land use rights of its subsidiary Guizhou Baite at No.
189, Hengzhi Road, No.
550 Baiyun North Road, Maijia Town, Baiyun District, Guiyang City, and its factories and other buildings and structures for no less than 121 million yuan.
According to the data, 7 years ago, Kang Enbei has spent 1.
95 billion yuan to acquire
Guizhou Baite.
Guizhou Baite's business income mainly comes from its leading variety of danshen chuanqiazine injection, over the years the annual sales revenue of the product accounts for more than 95% of the operating income of Guizhou Baite company, but also brought a large performance contribution to Kangenbei, but by the key monitoring of rational use of drug catalog, medical insurance control costs and other factors, the product sales continued to decrease or even to almost no market sales, the product has been discontinued in December 2019, and on February 23, 2021 to cancel the
。 Previously, Kang Enbei has impaired Guizhou Baite, in 2019 and 2020, a total of 820 million yuan
in two years.
ConnBei is a pharmaceutical listed enterprise
integrating drug research and development, production, sales and cultivation of medicinal materials.
The 2022 semi-annual performance report shows that the company was affected by the epidemic and other factors, and achieved operating income of about 2.
846 billion yuan in the first half of the year, a year-on-year decrease of 8.
77%; Net profit attributable to shareholders of listed companies was about 209 million yuan, a decrease of 14.
96% year-on-year; Basic earnings per share were RMB0.
081, a decrease of 15.
63%
year-on-year.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.